凝血因子药物市场分析

doi:10.13523/j.cb.20170517

中国生物工程杂志

2017, Vol. 37

Issue (5): 133-139 DOI: 10.13523/j.cb.20170517

行业分析

凝血因子药物市场分析

李敏¹, 吴日伟²

1. 江西省科学院科技战略研究所南昌 330096;
2. 南昌高新技术产业开发区管理委员会南昌 330096

The Analysis of Coagulation Factors Market

LI Min¹, WU Ri-wei²

1. Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China;
2. Nanchang National High-Tech Industrial Development, Nanchang 330096, China

全文: PDF(510 KB) HTML

摘要：

凝血因子是一类特殊的药物，是血友病等血液疾病的治疗药物，目前已经成为血液制品的重要组成部分。国外已经有二十多种重组凝血因子药物上市，2015年全球重组凝血因子药物的市场规模已经达到78.54亿美元，未来还将持续增长，Baxalta公司的重组凝血因子产品销售额位居全球首位，达到28.40亿美元。国外有多种重组凝血因子处于研发阶段，其中长效重组凝血因子将成为新的市场增长点。国内各类凝血因子药物的批签发状况良好，且随着国家发展和改革委员会取消血液制品最高零售价，各类产品价格均有不同幅度增长，其中人纤原蛋白原增长幅度最高，达到189%。国产凝血因子市场空间巨大，但存在产品供给和研发力度不足等问题，发展受到限制，必须改革行业管理制度、提高血浆分离技术、加强重组产品研发。

关键词： 凝血因子; 国内凝血因子药物市场; 全球凝血因子药物市场

Abstract:

Coagulation factor is a kind of special drugs, which is the treatment drug for hemophilia and has become an important part of blood products. There are more than 20 kinds of recombinant coagulation factor listed in the global market and the market sales are 7.854 billion dollars in 2015. The sales of recombinant coagulation factors of Baxalta ranked first in the world, reaching 2.84 billion dollars. The issued institution of coagulation factors in domestic is good. With the abolishment of the maximum retail price of blood products by National Development and Reform Commission, the prices of all kinds of products have different ranges of growth. Among them, the growth rate of human fibrinogen is the highest, reaching 189%. There is great potential for domestic coagulation factor market. But some factors hinder the development of the market, such as products supply shortage and lacking of R&D efforts and so on. Reforming of the industry management system, improving the technology of plasma separation, strengthening the research and development of recombinant products is necessary now.

Key words: Global coagulation factor market Domestic coagulation factor market Coagulation factor

收稿日期: 2016-11-04 出版日期: 2017-05-25

ZTFLH:

Q81

基金资助:

江西省软科学资助项目（20151BBA10065,20161ACA10023）

通讯作者: 李敏 E-mail: limin20140701@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

李敏, 吴日伟. 凝血因子药物市场分析[J]. 中国生物工程杂志, 2017, 37(5): 133-139.

LI Min, WU Ri-wei. The Analysis of Coagulation Factors Market. China Biotechnology, 2017, 37(5): 133-139.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20170517 或 https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I5/133

[1] 血制品:潜在市场空间巨大. 招商证券, 2016, 19(7):48. Blood products:huge potential market space. China Merchants Securities, 2016, 19(7):48.
[2] 李陆, 阎嘉, 刘佳, 等. 凝血因子及血浆蛋白类制品的研究现状及发展前景. 现代生物医学进展, 2014, 14(18):3578-3580. Li L, Yan J, Liu J, et al. The research status and prospects of coagulation factors and plasma protein products. Progress in Modern Biomedicine, 2014, 14(18):3578-3580.
[3] Gao F. The viral safety and rational use of plasma derivative products. China Licensed Pharmacist, 2012, 9(9):37-41.
[4] Burnouf T. Recombinant plasma proteins. Vox Sang, 2011, 100(1):68-83.
[5] 王娅, 卢丽, 黄晓倩, 等. 国产血液制品生产供应现状及改善策略探讨. 中国输血杂志, 2016, 29(4):431-435. Wang Y, Lu L, Huang X Q, et al. Analysis and strategic suggestion on the situation and progress of plasma fractionation in China. Chinese Journal of Blood Transfusion, 2016, 29(4):431-435.
[6] 李敏. 中国血液制品行业分析. 中国生物工程杂志. 2016,36(9):119-125. Li M. The analysis of Chinese blood biologicals industry. China Biotechnology, 2016,36(9):119-125.
[7] 吕茂民, 王方, 赵雄, 等. 凝血因子与创伤止血. 军事医学, 2015, 39(3):211-215. Lu M M, Wang F, Zhao X, et al. Coagulation factor and traumatic hemostasis. Military Medical Science, 39(3):211-215.

[1]	王惠临,周凯强,朱红雨,王力景,杨仲璠,徐明波,曹荣月. 凝血因子VII及其重组表达新进展[J]. 中国生物工程杂志, 2021, 41(2/3): 129-137.
[2]	姜月华, 王海萍, 王健伟, 韩金祥, 洪涛. 线虫抗凝肽的研究进展[J]. 中国生物工程杂志, 2005, 25(S1): 57-61.
[3]	薛京伦. 中国的遗传病基因治疗研究[J]. 中国生物工程杂志, 1993, 13(2): 49-49.
[4]	睿中. 谁将克隆染色体?[J]. 中国生物工程杂志, 1985, 5(4): 71-72.
[5]	睿中. 克隆凝血因子Ⅷ[J]. 中国生物工程杂志, 1985, 5(3): 78-79.

Viewed

Full text

Abstract

Cited

Shared

Discussed